Emcure Pharmaceuticals Limited has officially appointed Mr. C S Muralidharan as an Independent Director. Following a successful remote e-voting process, shareholders have approved his appointment for an initial term of three consecutive years, effective from April 1, 2026. This appointment marks a strategic update to the company’s board composition.
Board Leadership Update
Emcure Pharmaceuticals Limited has announced the successful appointment of Mr. C S Muralidharan (DIN: 00014740) to its board of directors. The appointment serves to strengthen the company’s leadership and governance, with members formally approving the decision via a postal ballot process that concluded on April 24, 2026.
Terms of Appointment
Mr. Muralidharan will serve an initial term of 3 (three) consecutive years. The appointment is effective retroactively from April 1, 2026. The company has confirmed that the new director is not debarred from holding office and maintains no familial or professional relations with existing members of the board or key managerial personnel, ensuring a high standard of independent oversight for the organization.
Source: BSE
